Last edition
News about "Enspryng IL-6R inhibitor"
US FDA Approves Roche's Enspryng for Thyroid Eye Disease
The US FDA has approved Roche’s Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease (TED).
Enspryng IL-6R Inhibitor | 17/10/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members